Treatment Information

Back

Ovarian Cancer treatment details. Chemotherapy.

MD Anderson Cancer Center, University of Texas, Houston, TX, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Houston, TX
Treatments:ChemotherapyHospital:MD Anderson Cancer Center, University of Texas
Drugs:Journal:Link
Date:Nov 2010

Description:

Patients:
This study involved 30 women with epithelial ovarian cancer whose cancer had progressed following prior platinum-based chemotherapy. The median patient age was 63 years.

Treatment:
Patients were treated with a combination of two chemotherapy agents, azacitidine and carboplatin.

Toxicities:
The maximum toxicity level reported was grade 4, including neutropenia and thrombocytopenia. Also, 30% of patients experienced grade 3 fatigue and 13.3% reported grade 3 pain at injection site.

Results:
The median progression-free survival for this study was 3.7 months. The median overall survival was 14 months.

Support:
This study was supported by Pharmion Corp., makers of azacitidine (trade name: Vidaza).

Correspondence: Dr. Siqing Fu; email: [email protected]



Back